EP1292297A1 - Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase - Google Patents

Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase

Info

Publication number
EP1292297A1
EP1292297A1 EP01937066A EP01937066A EP1292297A1 EP 1292297 A1 EP1292297 A1 EP 1292297A1 EP 01937066 A EP01937066 A EP 01937066A EP 01937066 A EP01937066 A EP 01937066A EP 1292297 A1 EP1292297 A1 EP 1292297A1
Authority
EP
European Patent Office
Prior art keywords
patient
solvate
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01937066A
Other languages
German (de)
English (en)
Inventor
Ian AstraZeneca R & D Alderley COCKSHOTT
Barrington AstraZeneca R & D Alderley FURR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1292297A1 publication Critical patent/EP1292297A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un produit pharmaceutique, une dose quotidienne ou un schéma posologique, comprenant du 4'-cyano-α',α',α'-trifluoro-3-(4-fluorophénylsulphonyl)-2-hydroxy-2-méthylpropriono-m-toluidide (composé I) et de l'anastrozole. L'invention concerne également une méthode permettant d'obtenir sensiblement un effet anti-androgène et l'inhibition de l'aromatase sans causer d'augmentation supplémentaire des niveaux d'androgènes circulant.
EP01937066A 2000-05-23 2001-05-22 Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase Withdrawn EP1292297A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012293.7A GB0012293D0 (en) 2000-05-23 2000-05-23 Pharmaceutical combination
GB0012293 2000-05-23
PCT/SE2001/001163 WO2001089516A1 (fr) 2000-05-23 2001-05-22 Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase

Publications (1)

Publication Number Publication Date
EP1292297A1 true EP1292297A1 (fr) 2003-03-19

Family

ID=9892040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01937066A Withdrawn EP1292297A1 (fr) 2000-05-23 2001-05-22 Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase

Country Status (5)

Country Link
EP (1) EP1292297A1 (fr)
JP (1) JP2003534279A (fr)
AU (1) AU2001262834A1 (fr)
GB (1) GB0012293D0 (fr)
WO (1) WO2001089516A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949361B1 (fr) 2007-11-13 2017-03-22 Athenion AG Stéroïdes c-19 pour les traitement de la cellulite
CN102988313A (zh) * 2011-09-14 2013-03-27 北京以岭生物工程技术有限公司 一种阿那曲唑分散片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
DE3372965D1 (en) * 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8714013D0 (en) * 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
JPH09508125A (ja) * 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0189516A1 *

Also Published As

Publication number Publication date
AU2001262834A1 (en) 2001-12-03
WO2001089516A1 (fr) 2001-11-29
JP2003534279A (ja) 2003-11-18
GB0012293D0 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
AU2004281708B2 (en) Treating bone-related disorders with selective androgen receptor modulators
US5985868A (en) Methods and compositions for treating androgen-dependant diseases using optically pure R-(-) casodex
US4895715A (en) Method of treating gynecomastia
EA018699B1 (ru) Применение соединения селективного модулятора андрогеновых рецепторов
US20030134899A1 (en) Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
US4207315A (en) Process for treating proliferative skin diseases using certain diamino compounds
KR20010029495A (ko) 전립선 비대 및 전립선 암을 치료하기 위한 수단
US20030158160A1 (en) Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
JP2017522389A (ja) シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療
US20030114519A1 (en) Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
EP1292297A1 (fr) Combinaison pharmaceutique de bicalutamide et d'anastrozole permettant d'obtenir un effet anti-androgene et l'inhibition de l'aromatase
WO2002002107A1 (fr) Combinaison pharmaceutique de bicalutamide et de letrozole pour produire un effet anti-androgenique et une inhibition d'aromatase
US20080132568A1 (en) Compounds with anti-androgenic activity and the use thereof
WO2002080971A1 (fr) Compositions comprenant un agent bloquant du recepteur de l'androgene et un agent de sensibilisation a l'insuline et utilisation de ces compositions pour traiter le syndrome des ovaires polykystiques
WO2002002113A1 (fr) Combinaison pharmaceutique d'anti-androgene et de letrozole a effet anti-androgenique avec inhibition d'aromatase
WO2002002112A1 (fr) Combinaison pharmaceutique d'anti-androgene et d'anastrozole conçue pour produire un effet anti-androgene et une inhibition de l'aromatase
WO2021151905A1 (fr) Composés de tétrahydrocyclopenta[b]indole servant au traitement de maladie rénale
JP2004529182A (ja) 医薬組成物
US20050288230A1 (en) Non-steroidal anti-androgen therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041026